Charlie has over 40 years of professional experience in biomedical research, including 30+ years in the pharmaceutical and biotechnology industries. He currently provides consulting services on drug development with a focus on clinical and regulatory strategies. Charlie is also a member of the Board of Directors of T3D Therapeutics, a clinical stage drug development company engaged in the development of a new orally administered treatment for Alzheimer’s disease. Previously, he was Co-founder and CEO of Lineberry Research Associates (LRA), a privately held CRO and strategic consulting firm that provided drug development services to pharmaceutical and biotech companies both in the US and globally. The company’s client roster included large and medium sized multinational pharma companies as well as a broad mix of small pharma and biotech companies, many of which were start-up ventures. LRA received numerous awards in the business and scientific community for its sustained growth and success over more than a decade. Additionally, the company was highly regarded for its emphasis on corporate culture and community service. Prior to founding LRA, Charlie was Senior Director, Clinical Neurosciences at Burroughs Wellcome Co. (now GlaxoSmithKline), where he was responsible for clinical development programs in psychiatry, neurology and anesthesiology and supervised the successful submission of 18 INDs and 7 approved NDAs. Charlie has a Ph.D. in physiological psychology, NIH post-doctoral training in neurobiology, and has held teaching and research positions in the medical schools at the University of Florida, the University of Pittsburgh, and the University of North Carolina.